(Press-News.org) Shetland ponies' immune response to insect bites is helping scientists understand how people could be prevented from developing allergies.
The horse immune system can respond to midge bites in a way that prevents - rather than triggers - allergic reactions, researchers say.
The ponies' immune response to midge bites is similar to what happens in people with allergies, the team says. Understanding what triggers allergic reactions could help researchers come up with ways to stop people developing sensitivities.
It was previously thought that ponies which do not suffer an allergic reaction to bites do so because their immune system does not recognise allergens carried by the insects, and as a result does not respond.
However, researchers at the University of Edinburgh have shown for the first time that all horses respond and that their immune system can act in two different ways in response to the irritants in midge bites.
One of these responses produces allergy symptoms - such as itching and inflammation - while the other prevents an allergic reaction, researchers say.
The team found that after being exposed to midges, the horse immune system can release various types of factors - known as cytokines - which affect the behaviour of other cells.
Ponies that react to midge bites release cytokines - known as IL-4 - which trigger allergy symptoms. In ponies not sensitive to bites, another cytokine - INF-? - is released, which blocks different immune cells that would otherwise trigger allergic reactions, researchers say.
By priming the human immune system to respond to allergens in a way that does not trigger reactions, it could be possible to prevent people developing sensitivities, the team says.
Allergies are caused by a complex interaction between genetic and environmental factors. Researchers say the reason why some individuals develop sensitivities to certain substances, while others do not, is not fully understood. It is unclear what causes the immune system to activate a protective response over an allergic one, the team says.
The study, published in the journal PLOS ONE, was funded by the Dutch Foundation for Technical Sciences (STW) and was carried out in collaboration with researchers in the Netherlands.
Dr Dietmar Zaiss, of the University of Edinburgh's School of Biological Sciences, who led the study, said: "To our knowledge, this is the very first study of a natural allergic disease in which we can show that immune responses to allergens can take two directions, either leading to allergy or to tolerance. We believe this finding could have direct practical implications, for example by helping immune responses to choose the "right" direction in individuals who we would like to protect from developing occupation-associated allergies."
INFORMATION:
April 23, 2015, Vienna, Austria: A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver CongressTM 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis. The research was supported by the Wellcome Trust and the NIHR.
In the Liraglutide Efficacy and Action in NASH (LEAN) trial, overweight patients with biopsy-confirmed ...
April 23, 2015, Vienna, Austria: Phase III results revealed today at The International Liver Congress™ 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.
HIV co-infection more than triples the risk of hepatitis C-related liver disease, liver failure and liver-related death. Co-infection can also complicate the management of HIV infection.
In the ALLY-2 ...
April 23, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.
Using exome sequencing - a technique for sequencing all the protein-coding genes in a genome - the study identified relationships between environmental ...
April 23, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.
SOLAR 2 data are presented for 328 HCV genotype-1 or -4 treatment-naive or treatment-experienced ...
April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.
A pooled analysis of data from two randomised trials comparing vitamin E versus placebo, and the placebo group from another ...
April 23, 2015, Vienna, Austria: As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver CongressTM 2015 has shown the devastating impact the infection has on their daily lives.
Research conducted with the Ministry of Health in Brazil questioned 1,217 people infected with hepatitis B or C in Europe and America using an online survey tool. The aim of the research ...
April 23, 2015, Vienna, Austria: Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
In clinical studies, remogliflozin etabonate was shown to significantly improve insulin sensitivity and beta cell function, as well as reduce body weight and levels of alanine aminotransferase (ALT). In pre-clinical studies, remogliflozin ...
April 23, 2015, Vienna, Austria: New data from an ongoing Phase III trial revealed today at The International Liver CongressTM 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir®) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT). The data demonstrate that intravenous Civacir given both peri- and post-LT prevents HCV-reinfection in patients who also received antiviral therapy (AVT) before their transplant operation.
Civacir is a hepatitis C immune globulin (HCIG) produced from pooled plasma ...
April 23, 2015, Vienna, Austria: Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).
An interim analysis of the study, revealed today at The International Liver Congress™ 2015, shows a significantly higher percentage of patients experienced NASH resolution and improvement in fibrosis after 48 weeks of treatment with silymarin compared to placebo.
NASH occurs when the liver becomes inflamed ...
April 23, 2015, Vienna, Austria: Many countries in the World Health Organization (WHO) European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress™ 2015.
The study highlights that less than one-third (27%) of WHO European Member States have national strategies in place that contain a surveillance component. Furthermore, only 64% have a national surveillance system for chronic hepatitis ...
